Boivin, DB. Influence of sleep-wake and circadian rhythm disturbances in psychiatric disorders. J Psychiatry Neurosci
2000; 25: 446–58.
Germain, A, Kupfer, DJ. Circadian rhythm disturbance in depression. Human Psychopharmacol
2008; 23: 571–85.
Pandi-Perumal, SR, Trakht, I, Spence, DW, Srinivasan, V, Dagan, Y, Cardinali, DP. The roles of melatonin and light in the pathophysiology and treatment of circadian rhythm sleep disorders. Nat Clin Pract Neurol
2008; 4: 436–47.
Millan, MJ, Gobert, A, Lejeune, F, Dekeyne, A, Newman-Tancredi, A, Pasteau, V, et al.
The novel melatonin agonist agomelatine (S20098) is an antagonist at 5-hydroxytryptamine2C receptors, blockade of which enhances the activity of frontocortical dopaminergic and adrenergic pathways. J Pharmacol Exp Ther
2003; 306: 954–64.
Pandi-Perumal, SR, Trakht, I, Srinivasan, V, Spence, DW, Masetroni, GJM, Zisapel, N, et al.
Physiological effects of melatonin: role of melatonin receptors and signal transduction pathways. Prog Neurobiol
2008; 85: 335–53.
San, L, Arranz, B.
Agomelatine: a novel mechanism of antidepressant action involving the melatonergic and the serotonergic system. Eur Psychiatry
2008; 23: 396–402.
Tardito, D, Molteni, R, Popoli, M, Racagni, G.
Synergistic mechanisms involved in the antidepressant effects of agomelatine. Eur Neuropsychopharmacol
2012; 22 (suppl 3): S482–6.
Molteni, R, Calabrese, F, Pisoni, S, Gabriel, C, Racagni, G, Riva, MA. Synergistic mechanisms in the modulation of the neurotrophin BDNF in the rat prefrontal cortex following acute agomelatine administration. World J Biol Psychiatry
2010; 11: 148–53.
Sen, S, Duman, R, Sanacora, G.
Serum brain-derived neurotrophic factor, depression, and antidepressant medications: meta-analyses and implications. Biol Psychiatry
2008; 64: 527–32.
Sharpley, AL, Rawlings, NB, Brain, S, McTavish, SFB, Cowen, PJ. Does agomelatine block 5-HT2c receptors in humans?
2011; 213: 653–5.
Krauchi, K, Cajochen, C, Mori, D, Graw, P, Wirz-Justice, A.
Early evening melatonin and S-20098 advance circadian phase and nocturnal regulation of core body temperature. Am J Physiol
1997; 272: R1178–88.
Leproult, G, Van Onderbergen, A, L'hermite-Balériaux, M, Van Cauter, E, Copinschi, G.
Phase-shifts of 24-h rhythms of hormonal release and body temperature following early evening administration of the melatonin agonist agomelatine in healthy older men. Clin Endocrinol
2005; 63: 298–304.
British Medical Association, Royal Pharmaceutical Society. British National Formulary (64th edn, September 2012). BMJ Group & Pharmaceutical Press, 2012.
Hickie, IB, Rogers, N.
Novel melatonin-based therapies: potential advances in the treatment of major depression. Lancet
2011; 378: 621–31.
Singh, SP, Singh, V, Kar, N.
Efficacy of agomelatine in major depressive disorder: meta-analysis and appraisal. Int J Neuropsychopharmacol
2012; 15: 417–28.
Barbui, C, Cipriani, A.
Agomelatine and the brave old world of narrative-based medicine. Evid Based Ment Health
2012; 15: 2–3.
Rihmer, Z, Dome, P, Baldwin, DS, Gonda, X.
Psychiatry should not become hostage to placebo: an alternative interpretation of antidepressant-placebo differences in the treatment response in depression. Eur Neuropsychopharmacol
2012; 22: 782–6.
Zajecka, J, Schatzberg, A, Stahl, S, Caputo, A, Post, A.
Efficacy and safety of agomelatine in the treatment of major depressive disorder: a multicentre, randomized, double-blind, placebo-controlled trial. J Clin Psychopharmacol
2010; 30: 135–44.
Montejo, A, Majadas, S, Rizvi, SJ, Kennedy, SH. The effects of agomelatine on sexual function in depressed patients and healthy volunteers. Hum Psychopharmacol
2011; 26: 537–42.
Sparshatt, A, McAllister-Williams, RH, Baldwin, DS, Haddad, PM, Bazire, S, Weston, S, et al.
A naturalistic evaluation and audit database of agomelatine: clinical outcome at 12 weeks. Acta Psychiatr Scand
2013; 128: 203–11.
Lewy, AJ. Circadian misalignment in mood disturbances. Curr Psychiatry Rep
2009; 11: 459–65.